Huons Global’s subsidiary, HuonsLab, recently introduced its formulation-switching platform technology utilizing human-derived hyaluronidase, along with its major pipelines, at a global bio industry event.


According to an announcement on March 17, HuonsLab actively promoted its human-derived hyaluronidase platform, ‘HyDIFFUZE’, by participating in the Korea Pavilion at ‘Bio China 2026 (BIO CHINA 2026)’, which was held recently in Suzhou, Jiangsu Province, China.


Exhibition booth of Huons Lab at the Korea Pavilion of 'Bio China 2026'. Huons Lab

Exhibition booth of Huons Lab at the Korea Pavilion of 'Bio China 2026'. Huons Lab

View original image

Bio China 2026, now in its 11th year, is the largest medical industry exhibition in China, with about 400 companies, including global pharmaceutical companies and major Chinese bio enterprises, participating in the exhibition. It is reported that more than 30,000 attendees from over 40 countries took part in the event.


This year, with increasing demand for collaborations between Korean companies and Chinese partners, the ‘Korea Pavilion’ was established for the first time at Bio China 2026. The Korea Health Industry Development Institute, Korea Trade-Investment Promotion Agency (KOTRA), and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association jointly operated the pavilion. Twenty-one companies, including HuonsLab, received support and engaged in consultations for technology transfer, investment attraction, and clinical cooperation.


HuonsLab is developing a technology that uses hyaluronidase, a substance that breaks down hyaluronic acid (HA) present in the subcutaneous layer to aid in drug dispersion, to convert antibody drug intravenous (IV) formulations into subcutaneous injection (SC) formulations.


HyDIFFUZE incorporates HuonsLab’s patented recombinant human hyaluronidase manufacturing process, which offers advantages such as high purity, high activity (activity per mass), and improved production yield. Additionally, since it is designed based on the same nucleotide sequence as natural human hyaluronidase, the company aims to secure competitiveness in terms of safety.


HuonsLab stated that in vivo studies based on HyDIFFUZE confirmed that it demonstrated equivalent pharmacokinetics (PK) and drug diffusion efficacy to original SC formulations, and that it can be applied to a variety of antibodies and modalities.


The company also introduced its key pipeline, HYDIZYME™ injection. HYDIZYME™ is an independent (stand-alone) product with the same sequence as Halozyme’s original hyaluronidase drug, ‘Hylenex’.


A HuonsLab representative said, “By introducing the HyDIFFUZE platform at BIO CHINA, we were able to identify possibilities for technology transfer, co-development with Chinese bio companies, and collaboration in the Chinese market,” and added, “Even as a stand-alone product, HYDIZYME™ has broad potential applications in plastic surgery, dermatology, aesthetics, pain, and edema treatment, attracting strong interest from several overseas companies.”



Meanwhile, in December last year, HuonsLab applied for domestic marketing authorization for its naturally derived recombinant human hyaluronidase, HYDIZYME™ injection. Once marketing approval is obtained, the company plans to launch it as a stand-alone product in plastic surgery, dermatology, pain, and edema treatment fields.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing